Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the Jaw: A review of 282 patients

Journal of the Canadian Dental Association

Volumn 77, Issue , 2011, Pages

  Bonacina, Riccardo ^a   Mariani, Umberto ^a   Villa, Francesco ^a   Villa, Alessandro ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; JAW DISEASE; MALE; MIDDLE AGED; NEOPLASM; RISK FACTOR;

ADULT; AGED; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; MALE; MIDDLE AGED; NEOPLASMS; OSTEONECROSIS; RISK FACTORS;

EID: 82955246367     PISSN: 07098936     EISSN: 14882159     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer J Oncol Pract 2006;2(1):7-14
2. Assael LA. New foundations in understanding o steonecrosis of the jaws. J Oral Maxillofac Surg. 2004;62(2):125-6 (Pubitemid 38140670)
3. Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg. 1982;4(3):251-3 (Pubitemid 12172078)
4. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61(10):1238-9. (Pubitemid 37193509)
5. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011;1218:38-46.
6. Markiewicz MR, Margarone JE, 3rd, Campbell JH, Aguirre A Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136(12):1669-74 (Pubitemid 41810028)
7. Watts NB. Treatment of osteoporosis with bisphosphonates Endocrinol Metab Clin North Am. 1998;27(2):419-39 (Pubitemid 28285873)
8. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191-200.
9. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphospho-nate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136(12):1658-68 (Pubitemid 41810027)
10. Fournier P, Boissier S, Filleur S, Guglielmi J, Carbon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ven-tral prostate in castrated rats. Cancer Res. 2002;62(22):6538-44 (Pubitemid 35364119)
11. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(2):186-93. Epub 2007 Apr 20
12. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteone-crosis of the jaw \- 2009 update. Aust Endod J. 2009;35(3):119-30
13. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphos-phonate therapy. J Dent Res. 2007;86(11):1013-21.
14. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67(5 Suppl):61-70
15. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99-102
16. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases J Cancer Res Clin Oncol. 2010;1 36(8):1117-24. Epub 2010 May 28
17. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkei G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44(9):857-69. Epub 2008 Feb 20
18. Badros A, Weikel D, Salama A, Golouveba O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24(6):945-52 (Pubitemid 46638849)
19. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117-20. Epub 2008 Aug 9
20. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Falsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-91 (Pubitemid 351229318)
21. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-57. Epub 2003 Sep 8. (Pubitemid 46606220)
22. Favus MJ. Diabetes and the risk of osteonecrosis of the jaw. J Clin Endocrinol Metab. 2007;92(3):817-8
23. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphos-phonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92(3):1172-5. Epub 2006 Dec 19. (Pubitemid 46465699)
24. Sambrook PN, Ebeling P. Osteonecrosis of the jaw. Curr Rheumatol Rep. 2008;10(2):97-101